Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
zj1DaykmKg0XR9wd
Écouter
